Alternative pathway blockade via factor B inhibition limits C3 cleavage, amplification loop activity, and downstream membrane ...
Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
Severe posttransfusion hyperhemolysis in a sickle cell patient produced profound anemia and lactic acidosis; terminal complement blockade with eculizumab stabilized hemolysis and enabled recovery.
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the ...
Cedars-Sinai investigators have identified a genetic variant that increases people's risk of developing perianal Crohn's disease, the most debilitating manifestation of Crohn's disease. Science X ...
Annexon (NASDAQ:ANNX) President and CEO Doug Love outlined the company's late-stage pipeline and regulatory plans during a ...
Novartis Pharmaceuticals Canada Inc. ("Novartis Canada") announced today that Health Canada has granted a Notice of Compliance (NOC) for Fabhalta® (iptacopan capsules) for the treatment of adult ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results